A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.

@article{Moayedi2013ARD,
  title={A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.},
  author={Behjat Moayedi and Marjan Gharagozloo and Nafiseh Esmaeil and Mohammad Reza Maracy and Hamid Hoorfar and Mohsen Jalaeikar},
  journal={European journal of haematology},
  year={2013},
  volume={90 3},
  pages={
          202-9
        }
}
OBJECTIVE Thalassemia is one of the most common genetic disorders worldwide. Chronic blood transfusions treat the underlying anemia but may lead to iron toxicity. Effective iron chelation remains one of the main targets of clinical management of thalassemia major. In this study, iron-chelating activity of silymarin, a flavonolignan isolated from silybum marianum, was examined in β-thalassemia major. METHODS Patients were treated with the combination of desferrioxamine and silymarin (Legalon… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 15 CITATIONS

Iron-chelating effect of silymarin in patients with β-thalassemia major: A crossover randomised control trial.

  • Phytotherapy research : PTR
  • 2018
VIEW 14 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Silibinin: an old drug for hematological disorders

  • Oncotarget
  • 2017
VIEW 3 EXCERPTS
CITES BACKGROUND

Optimizing the diagnosis and the treatment of iron overload diseases.

  • Expert review of gastroenterology & hepatology
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND